submit to the journals

Videos

As well as peer-reviewed journals, touchONCOLOGY also provide video interviews, procedures and general updates on the latest trends within the area, as well as featuring carefully selected video from our partners.
Wadie Bahou, ASH 2018 - Platelets and Platelet-related Biomarkers in Tumor Biology and Metastasis
Dr Wadie Bahou answers our questions about the role of platelets in tumor biology and metastasis and the significance and usefulness of platelet-related biomarkers in the detection and monitoring of hematologic and oncologic diseases. Questions: 1. What is the role of platelets in tumor biology...
Austin Kulasekararaj, ASH 2018 - Treatments for Paroxysmal Nocturnal Hemoglobinuria
In this interview filmed at ASH 2018, Dr Austin Kulasekararaj discusses the phase III non-inferiority study investigating ravulizumab (ALXN1210) versus eculizumab in adult patients with paroxysmal nocturnal hemoglobinuria in patients currently treated with eculizumab. He then goes on to discuss how...
Morie A Gertz, ASH 2018 - Hereditary TTR Amyloidosis and the NEURO-TTR Study
We spoke to Professor Morie Getz at ASH 2018 about the current unmet needs in treatment of hereditary TTR amyloidosis, antisense technology, inotersen and the NEURO-TTR study. Questions: 1. What is hereditary TTR amyloidosis and what are the unmet needs in its treatment? (0:10) 2. Could you...
Nicolaus Kröger, ASH 2018 - Treatment of Myelodysplastic Syndrome in Elderly Patients
Professor Nicolaus Kröger spoke to us at ASH 2018 about the major unmet needs in the treatment of myelodysplastic syndrome in elderly patients, and his phase III study comparing 5-azacytidine induction followed by allogeneic stem cell transplantation versus continuous 5-azacytidine according to...
Dirk Schadendorf, ESMO 2018 – Encorafenib plus Binimetinib for BRAF-mutant Metastatic Melanoma
In this interview, filmed at ESMO 2018, Professor Schadendorf discusses the use of encorafenib plus binimetinib for BRAF-mutant metastatic melanoma. Questions: 1. Could you tell us a little about the efficacy and safety findings of the COLUMBUS study that have led to the recent European...
Daniel A Vorobiof, ESMO 2018 – Prevalence of Cancer-related Fatigue
Dr Daniel A Vorobiof, ​Chief Medical Officer at Belong.Life, New York, NY, US, provides an overview of the findings of his study on the impact of cancer-related fatigue on patients and caregivers, and options of management and prevention.​ Belong.Life is the world’s largest professional social...
Do-Youn Oh, ESMO 2018 – M7824 for the Treatment of Biliary Tract Cancer
In this interview, filmed at ESMO 2018, Dr Do-Youn Oh highlights the importance of these results for biliary tract cancer, and where she thinks future research could lead. Questions: 1. What was the background and rationale behind the phase 1 study investigating M7824 in biliary tract cancer...
Marc Peeters, ESMO 2018 – Using Biomarkers to Guide Treatment in Colorectal Cancer
In this interview at ESMO 2018, Marc Peeters talks to touchONCOLOGY about colorectal cancer tumour location and biomarkers. He explains that left-sided cancers have a better prognosis and suggests some possible reasons for this. Dr Peeters also discusses how the use of biomarkers has developed in...
Eva C Winkler, ESMO 2018 – Financial Toxicity in German Cancer Patients: How Does a Chronic Disease Impact the Economic Situation?
There is a lack of consistency regarding what constitutes as financial toxicity and how to measure it in patients who have cancer. At this year’s ESMO, we met up with Dr Eva Winkler to learn more about this under-researched topic. As patients with cancer live longer, their financial burden...
Raffaele Califano, ESMO 2018 – Mechanisms of Resistance in Non-small Cell Lung Cancer
In this interview, at ESMO 2018, Dr Raffaele Califano talks to touchONCOLOGY about epidermal growth factor receptor (EGFR) expression in non-small cell lung cancer (NSCLC). He explains the importance of detecting EGFR activity prior to treatment in order to treat the patient effectively. Dr...
Matti Aapro, ESMO 2018 – Immunotherapy in Elderly Patients
Elderly patients are often under-represented in clinical trials and therefore may not receive the necessary treatment. Dr Matti Aapro explains that elderly patients should receive immunotherapy under the same circumstances as younger patients. While they may experience more treatment-related...
Byoung Chul Cho, ESMO 2018 – M7824 for the Treatment of Squamous Cell Carcinoma of the Head and Neck
M7824 is a bifunctional fusion protein which targets transforming growth factor-beta (TGF-beta) and programmed death-ligand 1 (PD-L1). This makes it suited to HPV-positive squamous cell carcinoma of the head and neck, as the TGS signalling pathway in this indication is frequently dysregulated. At...
Rita Laeufle, ESMO 2018 – Patient Selection for Abituzumab in Metastatic Colorectal Cancer
The Poseidon study was a phase I/II study in second-line KRAS mild-type metastatic colorectal cancer (mCRC) that did not meet its endpoint of progression-free survival, but did suggest a subgroup of patients with high alpha v beta 6 integrin expression who would benefit from abituzumab. In this...
Paolo A Ascierto, ESMO 2018 – Developments in the Treatment of Advanced Melanoma
We met with Dr Paolo Ascierto at ESMO 2018 to discuss the recent developments in the treatment of advanced melanoma. In this interview with touchONCOLOGY, Dr Ascierto reviews some of the recent trials investigating various immunotherapy combinations, and how survival rates have increased over the...
Josep M Piulats, ESMO 2018 – Rucaparib Treatment for Prostate Cancer
The current standard of care for prostate cancer can sometimes cease to be effective, causing the cancer to worsen. The TRITON2 and TRITON3 studies are looking at the PARP inhibitor, rucaparib, in the treatment of prostate cancer with BRCA1 and BRCA2 mutations. In addition, the TRITON trials are...

Out Now